Summary & Overview
HCPCS J7320: Hyaluronan (GenVisc 850) for Intra-articular Injection, 1 mg
HCPCS Level II code J7320 represents a single 1 mg unit of hyaluronan derivative (GenVisc 850) formulated for intra-articular injection, a viscosupplementation therapy used to manage joint pain. Nationally, this code is relevant for outpatient musculoskeletal care, orthopedics, rheumatology, and pain management settings where intra-articular injections are administered. The code matters because it indexes a specific product and unit size, informing billing, utilization tracking, and coverage determinations across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical indication and typical site of service, payer coverage considerations and common billing modifiers, and benchmarking context where available. The publication summarizes reimbursement benchmarks, common administrative issues when billing for viscosupplementation, and implications for coding accuracy.
This piece provides clinicians, billing staff, and policy analysts with a concise reference to HCPCS Level II code J7320, clarifying its clinical role, administrative considerations, and where to look for payer-specific policies and coverage rules. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7320 describes hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg. This billing code represents a single-unit dose of an injected viscosupplement used to treat joint pain, delivered via intra-articular injection into a synovial joint. The typical site of service for this treatment is an office, outpatient clinic, or ambulatory surgical center where joint injections are performed.
Service type: Intra-articular viscosupplement injection.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with chronic knee osteoarthritis presents to an outpatient orthopedic clinic with worsening medial knee pain and functional limitation despite conservative measures (physical therapy, oral NSAIDs, and activity modification). The clinician reviews prior imaging demonstrating joint space narrowing and osteoarthritic changes. After a shared decision process, the patient receives an intra-articular injection of a hyaluronan derivative (J7320, GenVisc 850, 1 mg) to provide viscosupplementation for symptomatic relief.
The clinical workflow: the patient checks in at the ambulatory clinic; informed consent and medication allergy review are completed; the knee is prepped with antiseptic; local anesthetic may be used; the clinician performs an aseptic intra-articular injection of J7320 under anatomic or ultrasound guidance; post‑procedure observation occurs for a short recovery period; billing is submitted with the appropriate HCPCS code J7320 and any applicable modifier(s) documenting specifics of the service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default reporting |